Needham & Company analyst Chad messer downgraded Progenics Pharmaceuticals (NASDAQ: PGNX) from Strong Buy to Buy with a price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Downgrades

Progenics Pharma (PGNX) Reports Addition of AZEDRA (iobenguane I 131) to National Comprehensive Cancer Network Guidelines for Pheochromocytoma and ParagangliomaSeptember 17, 2018 6:02 AM Progenics Pharmaceuticals (PGNX) Sell-Off 'Seems Overdone' - BTIGSeptember 13, 2018 11:53 AM